Electra Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
230 E Grand Ave Ste S100, South San Fran...Phone Number
(888) 743-2290Website
www.electra-therapeutics.comRevenue
$8.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. The companys lead product candidate, ELA026, is a first in class monoclonal antibody that targets signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological myeloid cells and T lymphocytes. ELA026 is currently in pivotal development for secondary hemophagocytic lymphohistiocytosis (sHLH) and is also being evaluated in additional indications. Electra is further advancing a second SIRP-targeted program, ELA822, designed to selectively deplete activated T lymphocytes, with broad potential across immunology and inflammation (I&I).Explore more
Electra Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Electra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Electra Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Electra Therapeutics has new funding data
Product Launch: Get notified when Electra Therapeutics launches new products
Check if Electra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Electra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Electra Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Electra Therapeutics
Click to see if Electra Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Electra Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Electra Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Electra Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Electra Therapeutics.
Electra Therapeutics financials insights
Gather financial insights about Electra Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$84M
2025
Series C
$183M
Stock/Share Issuance
$134.2M
Electra Therapeutics Tech Stack
A closer look at the technologies used by Electra Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
, according to a high-level source in accounting, is in the midst of initiatives related to technical accounting. The organization is currently evaluating NetSuite. Electra Therapeutics will be increasing funding to support these efforts. The organization is focusing on specific tax and accounting topics which require audit review as part of these initiatives.
Spending/Investment, Accounting, Financial Planning, Audit, Financial Reporting, Internal Audit & Control, Finance
Pain Point
Project
, according to a high-level source in accounting, is experiencing challenges related to project accounting.
Pain Point, Accounting, Financial Reporting, Finance
Project
Accounting, Financial Reporting, Finance
Electra Therapeutics News & Media
Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that it will present at the 44th annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, CA.Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced it will present two posters on the ELA026 clinical program in secondary hemophagocytic lymphohistiocytosis (sHLH) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9 in Orlando, Florida.Electra Therapeutics secures regulatory designations and funding for lead sHLH candidate
The drug candidate has been given breakthrough and priority medicines designations from the FDA and EMA respectivelyUAE's Mubadala Capital Joins USD 183M Round for US Biotech Electra Therapeutics
Electra Therapeutics raised USD 183M in Series C funding, with participation from Mubadala Capital to fund its clinical stage.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Electra Therapeutics
Sign Up For FreeTo access detailed company insights
Electra Therapeutics is a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. The companys lead product candidate, ELA026, is a first in class monoclonal antibody that targets signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological myeloid cells and T l... Read More
